CN107412721A - 一种降血糖苦瓜多肽复方胶囊及其制备方法 - Google Patents
一种降血糖苦瓜多肽复方胶囊及其制备方法 Download PDFInfo
- Publication number
- CN107412721A CN107412721A CN201710833327.0A CN201710833327A CN107412721A CN 107412721 A CN107412721 A CN 107412721A CN 201710833327 A CN201710833327 A CN 201710833327A CN 107412721 A CN107412721 A CN 107412721A
- Authority
- CN
- China
- Prior art keywords
- bitter gourd
- gourd polypeptide
- extract
- content
- hypoglycemic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000009811 Momordica charantia Nutrition 0.000 title claims abstract description 146
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 131
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 129
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 129
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 title claims abstract description 114
- 239000002775 capsule Substances 0.000 title claims abstract description 53
- 150000001875 compounds Chemical class 0.000 title claims abstract description 34
- 230000002218 hypoglycaemic effect Effects 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 244000078912 Trichosanthes cucumerina Species 0.000 title abstract 7
- 239000000284 extract Substances 0.000 claims abstract description 107
- 229930182494 ginsenoside Natural products 0.000 claims abstract description 32
- 229940089161 ginsenoside Drugs 0.000 claims abstract description 32
- 241001061264 Astragalus Species 0.000 claims abstract description 30
- 235000006533 astragalus Nutrition 0.000 claims abstract description 30
- 210000004233 talus Anatomy 0.000 claims abstract description 30
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 27
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 27
- 239000011651 chromium Substances 0.000 claims abstract description 27
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229910052804 chromium Inorganic materials 0.000 claims abstract description 23
- 239000000463 material Substances 0.000 claims abstract description 22
- 150000004676 glycans Chemical class 0.000 claims abstract description 21
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 21
- 239000005017 polysaccharide Substances 0.000 claims abstract description 21
- 239000011573 trace mineral Substances 0.000 claims abstract description 20
- 235000013619 trace mineral Nutrition 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 238000001035 drying Methods 0.000 claims abstract description 11
- 238000000227 grinding Methods 0.000 claims abstract description 9
- 241000196324 Embryophyta Species 0.000 claims abstract description 7
- 229930003935 flavonoid Natural products 0.000 claims abstract description 6
- 150000002215 flavonoids Chemical class 0.000 claims abstract description 6
- 235000017173 flavonoids Nutrition 0.000 claims abstract description 6
- 238000012216 screening Methods 0.000 claims abstract description 6
- 235000020985 whole grains Nutrition 0.000 claims abstract description 5
- 238000005550 wet granulation Methods 0.000 claims abstract description 4
- 244000302512 Momordica charantia Species 0.000 claims description 139
- 239000012528 membrane Substances 0.000 claims description 60
- 238000005096 rolling process Methods 0.000 claims description 34
- 235000009812 Momordica cochinchinensis Nutrition 0.000 claims description 29
- 235000018365 Momordica dioica Nutrition 0.000 claims description 29
- 238000000746 purification Methods 0.000 claims description 22
- 238000000108 ultra-filtration Methods 0.000 claims description 22
- 238000001471 micro-filtration Methods 0.000 claims description 16
- 239000012466 permeate Substances 0.000 claims description 16
- 238000001223 reverse osmosis Methods 0.000 claims description 13
- 239000012141 concentrate Substances 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 8
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 8
- 239000000853 adhesive Substances 0.000 claims description 8
- 230000001070 adhesive effect Effects 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 8
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 8
- 239000011812 mixed powder Substances 0.000 claims description 8
- 240000005373 Panax quinquefolius Species 0.000 claims description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 6
- 229920001353 Dextrin Polymers 0.000 claims description 5
- 239000004375 Dextrin Substances 0.000 claims description 5
- 241000219780 Pueraria Species 0.000 claims description 5
- 235000019425 dextrin Nutrition 0.000 claims description 5
- 239000002893 slag Substances 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 229940046374 chromium picolinate Drugs 0.000 claims description 4
- GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical group [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 claims description 4
- 239000007884 disintegrant Substances 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- BWWAFUZQSLIIIH-UHFFFAOYSA-N 2-phenyl-3H-chromen-3-id-4-one Chemical compound O1C(=[C-]C(=O)C2=CC=CC=C12)C1=CC=CC=C1 BWWAFUZQSLIIIH-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 3
- 239000004695 Polyether sulfone Substances 0.000 claims description 3
- 235000008434 ginseng Nutrition 0.000 claims description 3
- 229920002492 poly(sulfone) Polymers 0.000 claims description 3
- 229920006393 polyether sulfone Polymers 0.000 claims description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 206010013786 Dry skin Diseases 0.000 claims description 2
- 229940107131 ginseng root Drugs 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 238000001764 infiltration Methods 0.000 claims description 2
- 229940107628 american ginseng root Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 28
- 239000003814 drug Substances 0.000 abstract description 17
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 11
- 229940125396 insulin Drugs 0.000 abstract description 6
- 102000004877 Insulin Human genes 0.000 abstract description 5
- 108090001061 Insulin Proteins 0.000 abstract description 5
- 230000036541 health Effects 0.000 abstract description 4
- 230000035622 drinking Effects 0.000 abstract description 2
- 239000012634 fragment Substances 0.000 abstract description 2
- 235000013376 functional food Nutrition 0.000 abstract description 2
- 235000008216 herbs Nutrition 0.000 abstract description 2
- 230000010354 integration Effects 0.000 abstract description 2
- 239000008280 blood Substances 0.000 description 30
- 210000004369 blood Anatomy 0.000 description 30
- 239000008103 glucose Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- 238000000605 extraction Methods 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 230000033228 biological regulation Effects 0.000 description 11
- 229930003944 flavone Natural products 0.000 description 10
- 235000011949 flavones Nutrition 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 102000003746 Insulin Receptor Human genes 0.000 description 7
- 108010001127 Insulin Receptor Proteins 0.000 description 7
- 150000002212 flavone derivatives Chemical class 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 6
- 239000009636 Huang Qi Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000004153 islets of langerhan Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000000638 solvent extraction Methods 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 3
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 3
- 244000131316 Panax pseudoginseng Species 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- -1 flavone compound Chemical class 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010018473 Glycosuria Diseases 0.000 description 2
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 235000009815 Momordica Nutrition 0.000 description 2
- 241000218984 Momordica Species 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000005374 membrane filtration Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000007102 metabolic function Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- 238000009777 vacuum freeze-drying Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- IAJILQKETJEXLJ-KLVWXMOXSA-N (2s,3r,4r,5r)-2,3,4,5-tetrahydroxy-6-oxohexanoic acid Chemical compound O=C[C@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-KLVWXMOXSA-N 0.000 description 1
- 102000004277 11-beta-hydroxysteroid dehydrogenases Human genes 0.000 description 1
- 108090000874 11-beta-hydroxysteroid dehydrogenases Proteins 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 description 1
- 206010066786 Diabetic keratopathy Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001994 activation Methods 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- QOWZHEWZFLTYQP-UHFFFAOYSA-K chromium(3+);triformate Chemical compound [Cr+3].[O-]C=O.[O-]C=O.[O-]C=O QOWZHEWZFLTYQP-UHFFFAOYSA-K 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 235000012489 doughnuts Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical group O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 238000005360 mashing Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 229960004329 metformin hydrochloride Drugs 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 238000004537 pulping Methods 0.000 description 1
- RDRCCJPEJDWSRJ-UHFFFAOYSA-N pyridine;1h-pyrrole Chemical compound C=1C=CNC=1.C1=CC=NC=C1 RDRCCJPEJDWSRJ-UHFFFAOYSA-N 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一种降血糖苦瓜多肽复方胶囊及其制备方法,属于功能性食品保健或药品领域。该复方胶囊包括:3~5重量份苦瓜多肽提取物、2~4重量份人参皂苷提取物、1~3重量份葛根黄酮提取物、1~3重量份黄芪多糖提取物、以及微量元素铬0.6~0.8‰。其苦瓜多肽提取物中苦瓜多肽蛋白的含量不低于20%,其中分子量为5.5~7kDa的苦瓜多肽的含量占比例为18~25%,该多肽片段大小接近胰岛素分子量。其制备方法包括:将上述配方量的各原料与辅料混合后干燥过筛、经超微粉碎后采用湿法制粒、干燥过筛整粒,依规格填充胶囊。本苦瓜多肽复方胶囊为纯植物制剂,药食同源的组方合理,降血糖作用显著,可用于预防和治疗糖尿病。
Description
技术领域
本发明涉及功能性食品保健或药品领域,具体而言,涉及一种降血糖苦瓜多肽复方胶囊及其制备方法。
背景技术
随着人们生活水平不断提高和社会经济快速发展,我国糖尿病患者呈现出快速增长态势,患病人数约占全球糖尿病人总数三分之一。目前我国糖尿病发病率高达9.6%,糖尿病患者已超过1.1亿,且患病人数还在逐年递增。糖尿病的危害巨大,伴随糖尿病产生的糖尿病并发症也对患者的健康和生命构成巨大威胁。糖尿病古称为消渴,是指以多饮、多尿、多食及消瘦、疲乏、尿甜为主要特征的综合病症,化验检查其主要特征为高血糖及尿糖。消渴是由于阴亏燥热,五脏虚损所导致的以多饮、多食、多尿、形体消瘦为特征的病症。现代医学研究表明,糖尿病产生的主要原因是胰岛细胞受损、胰岛素分泌不足、或者机体功能紊乱造成机体对胰岛素敏感性下降,从而无法起到调节血糖的功能而引起糖尿病。
苦瓜属葫芦科苦瓜属植物,味苦性寒,是一种药食两用蔬菜。据《本草纲目》及《滇南本草》记载,苦瓜具有清热消暑、养血益气、补肾健脾、滋肝明目、降血糖的作用;苦瓜含有胰蛋白酶抑制剂,可抑制癌细胞所分泌出来的蛋白酶,防止恶性肿瘤,而且还具备有降血脂和血压的作用。近年来有关苦瓜的现代生物医学研究逐渐增多,1981年Khana报道了由苦瓜果实、种子和组织中提取出分子量为11kDa的成分,该成分经皮下注射对人体Ⅰ、Ⅱ型糖尿病具有良好的降血糖活性,但其口服后因肠道破坏活性较差;2003年刘璇报道了由苦瓜籽提取出6.8kDa的苦瓜多肽,该多肽具胰蛋白酶抑制活性和抗植物致病菌活性;2012年Blum A报道了由苦瓜中提取的粗提物可抑制11β-羟基类固醇脱氢酶Ⅰ型基因表达,用于Ⅱ型糖尿病治疗。中国专利文献号CN106974951A公开了治疗糖尿病的药物组合物,主要将西药格列齐特与中药人参、三七及维生素等复方。中国专利文献号CN107095975A公开了一种治疗糖尿病药方及其制备方法,将15种药材清洗沥干,翻炒后研磨成粉,沸水浸泡后直接服用。中国专利文献号CN106975010A公开了一种治疗糖尿病的中药组合物,含14种中药及药食同源的原料,包括葛根,黄芪和苦瓜等,将其直接粉碎、过筛混匀,灌胶囊。
虽然人们已经认识到苦瓜是具有降血糖功效的一种植物原料,并将其运用于糖尿病的治疗中,但同时存在一些问题:一是上述文献及有关治疗糖尿病的中药类植物制剂,大多将各类配方原料直接粉碎过筛后灌装服用、或直接加水煎煮或粉碎后加水煎服,没有关键成分的质量可控性及其含量,不能保证产品功效的稳定性及显著性;二是现有使用苦瓜提取物的降血糖类产品,苦瓜提取物多是以皂苷为主,实际上为“苦瓜皂苷”,或采用各类酶解反应或碱提酸沉得到苦瓜多肽蛋白质,但其含量不高、且制备时间周期长或某些步骤操作温度高,而天然活性的苦瓜多肽是有效调控血糖代谢的关键成分。因此,需要一种质量稳定且预防和治疗糖尿病效果显著的苦瓜制剂产品。
发明内容
本发明的目的在于提供一种降血糖苦瓜多肽复方胶囊,这种纯植物制剂的组方合理,能够有效的调控血糖代谢,可用于预防或者治疗糖尿病。
本发明的另一目的在于提供一种上述苦瓜多肽复方胶囊的制备方法,该方法具有技术工艺稳定,质量可控性强,保证产品核心成分的稳定性及显著性,且适合工业化生产。制备得到的产品具有降血糖效果好,功效稳定,吸收利用度高及服用方便的优点。
为了实现本发明的上述目的,特采用以下技术方案:
本发明提出一种降血糖苦瓜多肽复方胶囊,其包括:3~5重量份的苦瓜多肽提取物,苦瓜多肽提取物中苦瓜多肽蛋白的含量在20%以上;2~4重量份的人参皂苷提取物,人参皂苷提取物中人参皂苷的含量在15%以上;1~3重量份的葛根提取物,葛根提取物中总黄酮的含量在50%以上;1~3重量份的黄芪多糖提取物,黄芪多糖提取物中黄芪多糖的含量在15%以上;以及微量元素铬0.6~0.8‰。
进一步地,在本发明较佳实施例中,所述苦瓜多肽提取物中苦瓜多肽蛋白的含量不低于20%,分子量分布在4.5k~68kDa之间,其中分子量为5.5~7kDa的苦瓜多肽的含量占比例为18~25%,该蛋白多肽片段大小接近胰岛素分子量,是有效调控血糖代谢的关键功能成分,胰岛素受体结合能力极强,能激活胰岛受体蛋白信号通路,恢复受损胰岛细胞功能。
进一步地,在本发明较佳实施例中,所述苦瓜多肽复方胶囊还包括药用级或保健食品用辅料,所述辅料包括粘合剂、崩解剂、填充剂或润滑剂中的至少一种或几种,优选为微晶纤维素,抗性糊精,山梨糖醇、预胶化淀粉、交联聚维酮中的一种或几种。
进一步地,在本发明较佳实施例中,所述人参皂苷提取物是通过提取人参或西洋参根部制备得到。
进一步地,在本发明较佳实施例中,所述微量元素铬选自吡啶甲酸铬或富铬酵母。
进一步地,在本发明较佳实施例中,所述葛根总黄酮中葛根素的含量在40%以上。
进一步地,在本发明较佳实施例中,所述苦瓜多肽提取物的制备方法包括:用净化水浸提苦瓜原料,再离心去渣,得离心液;将所述离心液经过截留分子量为3μm~0.1μm的微滤膜系统进行过滤,除去大分子杂质,得到微滤膜透过液;将所述微滤膜透过液经过截留分子量为150kDa的卷式超滤膜纯化系统进行过滤,得超滤膜透过液;将所述超滤膜透过液再经截留分子量为800Da的卷式超滤膜纯化系统进行过滤,得到超滤膜截留液;将所述截留液经过截留分子量≥100Da的卷式高压反渗透膜系统进行浓缩,除去水分及部分残留无机盐和小分子杂质,得到浓缩液,所述浓缩液的固形物含量≥30%;将所述浓缩液进行干燥,得到多肽蛋白含量不低于20%的苦瓜多肽提取物粉。
进一步地,在本发明较佳实施例中,所述卷式超滤膜纯化系统采用两支膜并联使用,过滤膜为含有(PS)聚砜或(PFS)聚醚砜材料的过滤膜。经过卷式超滤膜系统进行纯化的操作温度为15~35℃,操作压力为0.3~0.8MPa。所述卷式高压反渗透膜浓缩系统采用四支膜串联使用,经过卷式高压反渗透膜进行浓缩的操作温度为15~35℃,操作压力为3.5~5.5MPa。
本发明还提供了一种降血糖苦瓜多肽复方胶囊的制备方法,其包括以下步骤:将所述苦瓜多肽提取物、所述人参皂苷提取物、所述葛根黄酮提取物、所述黄芪多糖提取物以及所述微量元素铬与载体辅料混合后干燥过筛、经振动磨式超微粉碎得粒度50μm以下混合粉料;采用湿法制粒法,用羟丙基纤维素HPC的乙醇溶液做粘合剂将所述混合粉料制成湿颗粒后,35~55℃干燥3~5小时并过40目筛网进行整粒,测定含量后依规格填充胶囊。
与现有技术相比,本发明的有益效果包括:本发明提供的一种降血糖苦瓜多肽复方胶囊及其制备方法,基于苦瓜降血糖的现代医学研究及糖尿病的消渴症理论,首先高效提取、分离、纯化大量具有稳定调控血糖代谢功能的特定分子量和序列的天然活性苦瓜多肽,其胰岛素受体结合能力极强,能激活胰岛受体蛋白信号通路及恢复受损胰岛细胞功能;另外结合中医药独特配方选用西洋参、葛根、黄芪,以及添加能增强人体胰岛素敏感性的微量元素铬,经复合制成的植物胶囊制剂,质量可控且降血糖效果显著,并可有效缓解或消除其他糖尿病并发症。本发明提供的治疗糖尿病的苦瓜多肽复方植物药的技术工艺稳定,质量可控性强,保证了产品核心成分的稳定性及显著性,制备得到的苦瓜多肽复方胶囊具有降血糖效果好,功效稳定,吸收利用度高及服用方便的优点。
附图说明
为了更清楚地说明本发明实施例的技术方案,下面将对实施例中所需要使用的附图作简单地介绍,应当理解,以下附图仅示出了本发明的某些实施例,因此不应被看作是对范围的限定,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他相关的附图。
图1为本发明实施例中苦瓜多肽提取物的多肽蛋白分子量分布的SDS-PAGE电泳图。
具体实施方式
下面将结合实施例对本发明的实施方案进行详细描述,但是本领域技术人员将会理解,下列实施例仅用于说明本发明,而不应视为限制本发明的范围。实施例中未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市售购买获得的常规产品。
本实施方式提供一种降血糖苦瓜多肽复方胶囊,其包括:
3~5重量份的苦瓜多肽提取物、2~4重量份的人参皂苷提取物、1~3重量份的葛根提取物、1~3重量份的黄芪多糖提取物、以及微量元素铬0.6~0.8‰。
可选的,苦瓜多肽胶囊包括:3.5~4.5重量份的苦瓜多肽提取物、2.5~3.5重量份的人参皂苷提取物、1.5~2.5重量份的葛根提取物、1.5~2.5重量份的黄芪多糖提取物、以及微量元素铬0.65~0.75‰。
更为具体的,苦瓜多肽胶囊包括:4重量份的苦瓜多肽提取物、3重量份的人参皂苷提取物、2重量份的葛根提取物、2重量份的黄芪多糖提取物、以及微量元素铬7‰。
苦瓜多肽是从苦瓜中提取得到的,但由于苦瓜多肽的种类多、分子量差异大、提取效率低,使得现有技术中苦瓜多肽提取物中苦瓜多肽的含量较低,进而影响其降糖效果。在本实施方式中,苦瓜多肽提取物中苦瓜多肽蛋白的含量在20%以上;其中,经研究表明天然苦瓜多肽蛋白的分子量为4.5k~68kDa,其中胰岛素受体结合能力极强、有效调控血糖代谢功能的关键多肽的分子量在5.5~7kDa,这部分苦瓜多肽片段大小接近胰岛素分子量,具有类胰岛素功能。因此,进一步优选的,苦瓜多肽提取物中分子量为5.5~7kDa的苦瓜多肽的含量占比例为18~25%,或者为19~24%,或者为23%。
进一步的,这种苦瓜多肽提取物的制备方法包括:
a.用净化水浸提苦瓜原料,再离心去渣,得离心液。
可选的,选用新鲜苦瓜或干燥苦瓜、苦瓜籽作为苦瓜原料,清洗的方法是:将苦瓜原料先经自来水清洗,再经电解式高浓度臭氧水清洗,清洗水中臭氧浓度达10~20mg/L,水流量150~450L/h,用以进一步清除农残药残、微生物残留等。
进一步的,用净化水浸提苦瓜原料的方法包括:在打浆破碎后的苦瓜原料倒入超声波辅助浸提罐,并加入5~10质量倍、38~52℃的净化水,利用缓冲盐调节体系pH=6.8~7即中性,进行逆流提取2~4次,每次30~60分钟。
进一步的,离心去渣的方法是:采用高速管式离心机或碟片式离心机进行离心。
b.将离心液经过截留分子量为3μm~0.1μm的微滤膜系统进行过滤,除去大分子杂质,得到微滤膜透过液。截留分子量为3μm~0.1μm的微滤膜过滤系统是指微滤膜的截留性能为3μm~0.1μm,例如:截留分子量为0.1μm的微滤膜系统是指其可以截留大于0.1μm的分子,使不大于0.1μm的分子通过。微滤膜透过液是指能通过微滤膜系统的液体。
进一步的,微滤膜过滤系统是由三支膜并联使用,过滤膜为有机管式、中空纤维或陶瓷微滤膜组成;经过微滤膜系统进行过滤的操作温度为15~35℃,操作压力为0.1~0.5MPa。
c.将微滤膜透过液经过截留分子量为50~200kDa的卷式超滤膜纯化系统进行过滤,得到超滤膜透过液。截留分子量为50~200kDa的卷式超滤膜纯化系统是指卷式超滤膜纯化系统的截留性能为50~200kDa,例如:截留分子量为200kDa的卷式超滤膜纯化系统是指其可以截留分子量大于200kDa的分子,使分子量不大于200kDa的分子通过。超滤膜透过液是指通过卷式超滤膜纯化系统的液体。
进一步的,将超滤膜透过液经过截留分子量为500~1000Da的卷式超滤膜纯化系统进行过滤,得到超滤膜截留液。截留分子量为500~1000Da的卷式超滤膜纯化系统是指卷式超滤膜纯化系统的截留性能为500~1000Da,例如:截留分子量为500Da的卷式超滤膜纯化系统是指其可以截留分子量大于500Da的分子,使分子量不大于500Da的分子通过。超滤膜截留液是指卷式超滤膜纯化系统截留的液体。
进一步的,卷式超滤膜纯化系统采用两支膜并联使用,过滤膜为含有(PS)聚砜或(PFS)聚醚砜材料的过滤膜。经过卷式超滤膜纯化系统进行纯化的操作温度为15~35℃,操作压力为0.3~0.8MPa。
d.将超滤膜截留液经过截留分子量为100~150Da的卷式高压反渗透膜系统进行浓缩,除去水分及小分子杂质,主要是部分残留无机盐离子,得到浓缩液,浓缩液的固形物含量≥30%。截留分子量为100~150Da的卷式高压反渗透膜系统是指卷式高压反渗透膜系统的截留性能为100~150Da,例如:截留分子量为100Da的卷式高压反渗透膜系统是指其可以截留分子量大于100Da的分子,使分子量不大于100Da的分子通过。浓缩液是指卷式高压反渗透膜系统截留的液体。
进一步的,卷式高压反渗透膜系统即为高压浓缩膜,具体是由聚酰胺复合材料膜制成。卷式高压反渗透膜系统浓缩系统采用四支膜串联使用。经过卷式高压反渗透膜系统进行浓缩的操作温度为15~35℃,操作压力为3.5~5.5MPa。
e.将浓缩液进行干燥,得到苦瓜多肽提取物。
进一步的,干燥方法为真空冷冻干燥或低温喷雾干燥,得到多肽蛋白含量不低于25%的苦瓜多肽提取物。
这种苦瓜多肽的制备方法采用多层次的膜分离纯化技术制备具有调节血糖功能的天然苦瓜多肽蛋白,免除酶解及高温灭酶步骤,生产周期短,分离纯化浓缩温度低,有效保证了制备的苦瓜蛋白多肽的天然活性及其高含量,得到的苦瓜多肽提取物中苦瓜多肽蛋白的含量至少高于25%,提取物产品中不含大豆蛋白多肽等其他非苦瓜来源的多肽蛋白。苦瓜多肽蛋白的分子量分子量为4.5k~68kDa,其中具有调节血糖功能、片段大小最接近胰岛素分子量的5.5~7kDa的苦瓜多肽片段的含量占比例为18~25%。因此得到的苦瓜多肽提取物具有非常好的调控血糖代谢效果,尤其是胰岛素受体的结合能力及降血糖的效果。
人参皂苷提取物,其中所含的人参皂苷的含量在15%以上。人参皂苷是一种三萜皂苷类化合物,主要存在于人参属药材中。较为优选的,本实施方式中的人参皂苷提取物是通过提取西洋参制备得到。西洋参中的主要成分为人参皂苷,其可通过溶剂提取法制备得到。从西洋参中提取的人参皂苷提取物可以降低血糖、调节胰岛素分泌、促进糖代谢和脂肪代谢,对治疗糖尿病有一定的辅助作用。
葛根提取物,是通过采用溶剂提取法提取中药材葛根制备得到,其中所含的主要成分为黄酮类化合物(例如葛根素、葛根黄酮苷、异黄酮苷等),其含量在50%以上,其具有扩张血管、降低血压、改善微循环的功效,可用于辅助治疗糖尿病。进一步的,总黄酮中葛根素的含量在40%以上,葛根素是葛根中最主要的药效成分,能够改善胰岛素敏感性并具有降血糖的作用,同时其对糖尿病慢性并发症如糖尿病肾病、糖尿病性心脏病、糖尿病性脑血管疾病、糖尿病性神经病变、糖尿病性视网膜病变等均有改善作用。其含量在40%以上,能够使得葛根提取物发挥更大的药效。
黄芪多糖提取物,是通过采用溶剂提取法提取中药材黄芪制备得到,黄芪多糖提取物中黄芪多糖的含量在15%以上。黄芪多糖是黄芪发挥作用的主要成分,其中所含的黄芪多糖包括己糖醛酸、葡萄糖、果糖、鼠李糖、阿拉伯糖、半乳糖醛酸和葡萄糖醛酸等,可作为免疫促进剂或调节剂,能够降低血糖、糖化血红蛋白和尿蛋白、增强体液免疫作用。
在本实施方式中,人参皂苷提取物、葛根提取物、黄芪多糖提取物,可以从市面上直接购买得到,或者也可采用溶剂提取法制备得到,溶剂提取法包括加热回流提取法、微波震荡提取法、煎煮法、浸渍法、渗漉法等。提取溶剂为水或乙醇水混合溶液体系。
微量元素铬,有助于胰岛素促进葡萄糖进入细胞内的效率,是血糖调节剂,可以预防糖尿病。进一步的,微量元素铬选自吡啶甲酸铬或富铬酵母。富铬酵母,是在酵母培养的过程中加入无机铬,通过酵母在生长过程中对铬的自主吸收和转化,使铬能够被人体更高效、更安全地吸收利用。吡啶甲酸铬是一种用于2型糖尿病的补充或供选择的微量元素,吡啶甲酸铬能够通过p38 MAPK活化作用影响摄取葡萄糖的摄取。
进一步的,苦瓜多肽复方胶囊还包括药用级或保健食品用辅料,辅料包括粘合剂、崩解剂、填充剂、以及润滑剂中的至少一种或几种。其中,粘合剂包括但不限于:微晶纤维素、藻酸盐、明胶和交联聚维酮;崩解剂包括但不限于:交联PVP、交联羧甲基淀粉钠、交联羧甲基纤维素钠、和低取代羟丙基纤维素;填充剂包括但不限于:预胶化淀粉、抗性糊精、麦芽糊精;润滑剂包括但不限于:硬脂酸镁、硬脂酸铝、滑石、聚乙二醇、山梨糖醇;进一步的,药用辅料还包括:润湿剂(如甘油)、表面活性剂(如十六烷醇)以及吸收促进剂、矫味剂、甜味剂、稀释剂等。
本实施方式还提供一种苦瓜多肽复方胶囊的制备方法,其包括:
步骤S1:将苦瓜多肽提取物、人参皂苷提取物、葛根黄酮提取物、黄芪多糖提取物以及微量元素铬与载体辅料混合后干燥过筛、经振动磨式超微粉碎得粒度50μm以下混合粉料。
步骤S2:采用湿法制粒法,用羟丙基纤维素HPC的乙醇溶液做粘合剂将所述混合粉料制成湿颗粒后,35~55℃干燥3~5小时并过40目筛网进行整粒,测定含量后依规格填充胶囊。
以下结合实施例对本发明的特征和性能作进一步的详细描述:
实施例1
本实施例提供一种降血糖苦瓜多肽复方胶囊,该苦瓜多肽复方胶囊包括:
苦瓜多肽提取物4Kg、人参皂苷提取物3Kg、葛根黄酮提取物2Kg、黄芪多糖提取物2Kg、微量元素铬0.7‰。
其中,苦瓜多肽提取物中苦瓜多肽的含量为28%,其中分子量为5.5~7kDa的苦瓜多肽的含量占比例为22%;人参皂苷提取物中人参皂苷的含量为25%;葛根提取物中总黄酮的含量为72%,总黄酮中葛根素的含量为48%;黄芪多糖提取物中黄芪多糖的含量为21%。
该苦瓜多肽胶囊的制备方法包括:将苦瓜多肽提取物、人参皂苷提取物、葛根提取物、黄芪多糖提取物以及微量元素铬与3%微晶纤维素、10%抗性糊精、3%硬脂酸镁、6%山梨糖醇等辅料混合后干燥过筛、经振动磨式超微粉碎得粒度20μm以下混合粉料;药用辅料混合后干燥、过筛后得混合药粉;用羟丙基纤维素HPC的乙醇溶液做粘合剂将所述混合粉料制成湿颗粒后,45℃干燥4小时并过40目筛网进行整粒,测定含量后依规格填充胶囊。
实施例2
本实施例提供一种具有降血糖作用的苦瓜多肽胶囊,该苦瓜多肽胶囊包括:
苦瓜多肽提取物3Kg、人参皂苷提取物4Kg、葛根提取物1Kg、黄芪多糖提取物3Kg、微量元素铬0.6‰。
其中,苦瓜多肽提取物中苦瓜多肽的含量为31%,其中分子量为5.5~7kDa的含量占比例为18%;人参皂苷提取物中人参皂苷的含量为15%;葛根提取物中总黄酮的含量为65%,总黄酮中葛根素的含量为45%;黄芪多糖提取物中黄芪多糖的含量为15%。
该苦瓜多肽胶囊的制备方法与实施例1一致。
实施例3
本实施例提供一种具有降血糖作用的苦瓜多肽胶囊,该苦瓜多肽胶囊包括:
苦瓜多肽提取物5Kg、人参皂苷提取物2Kg、葛根提取物3Kg、黄芪多糖提取物1Kg、微量元素铬0.8‰。
其中,苦瓜多肽提取物中苦瓜多肽的含量为25%,其中分子量为5.5~7kDa的含量占比例为20%;人参皂苷提取物中人参皂苷的含量为28%;葛根提取物中总黄酮的含量为60%,总黄酮中葛根素的含量在为40%;黄芪多糖提取物中黄芪多糖的含量为26%。
该苦瓜多肽胶囊的制备方法与实施例1一致。
其中,苦瓜多肽提取物的制备方法包括:
选用生长期较长,绿色偏黄、苦瓜籽粒较饱满的新鲜苦瓜作为原料,将苦瓜原料先经自来水清洗,再经电解式高浓度臭氧水清洗。清洗水中臭氧浓度15mg/L,水流量300L/h,以降低农残药残及微生物残留。将清洗后的苦瓜原料打浆破碎成过20目筛网的液态物料。将打浆破碎后的苦瓜原料倒入超声波辅助浸提罐,并加入8质量倍、50℃的净化水,利用缓冲盐调节体系pH≈7,进行超声辅助的逆流提取3次,每次30分钟。
采用高速管式离心机进行离心,并去渣,得离心液。将离心液经过截留分子量为1μm的中空纤维微滤膜系统进行过滤,操作温度为30℃,操作压力为0.3MPa,得微滤膜透过液。
先将微滤膜透过液分别经过截留分子量为200kDa的卷式超滤膜纯化系统进行过滤,操作温度为30℃,操作压力为0.8MPa,得超滤膜透过液;再将透过液经过截留分子量为800Da的卷式超滤膜纯化系统进行过滤,操作温度为30℃,压力为0.8MPa,得到超滤膜截留液。
将超滤膜截留液经过截留分子量为150Da的卷式高压反渗透膜系统进行浓缩,操作温度为30℃,操作压力为4MPa,得到固形物含量≥30%的浓缩液。采用真空冷冻干燥的方式将浓缩液进行干燥,得到苦瓜多肽提取物,其多肽蛋白的含量达26.5%。
采用凝胶电泳法对所制得的苦瓜多肽提取物中的多肽蛋白进行检测,如图1所示,图1为本发明实施例中苦瓜多肽提取物的多肽蛋白分子量分布的SDS-PAGE电泳图;由图1可知:按照本实施例提供的制备方法所制得的苦瓜多肽提取物中,分子量为6kDa左右的苦瓜多肽的含量占比例在22%以上,其片段大小接近胰岛素分子量,与胰岛素受体的结合能力强,能够有效激活胰岛素受体蛋白信号通路,恢复受损胰岛细胞功能。因此,按照本实施例的技术工艺得到的苦瓜多肽提取物中含有大量具有调节血糖功能的天然活性苦瓜多肽蛋白。
以下对实施例1、实施例2和实施例3提供的降血糖苦瓜多肽复方胶囊的降血糖活性进行测试评价:
一、实验方法:
1.造模:选取健康成年的SD雄性大鼠120只,体重150±20g,随机分成6组,每组20只。其中5组24小时后,腹腔注射链唑霉素(剂量为45mg/kg),注射72h后,禁食不禁水6h,尾静脉取血,测血糖;取血糖值≥16.8mM的大鼠继续造模,饲以高脂饲料;空白组在同等条件下腹腔注射等剂量的生理盐水,饲以普通饲料。四周后,尾静脉取血测血糖,代谢笼法测24h尿蛋白含量,空腹血糖(BG)值≥16.8mM,同时24h尿蛋白定量≥20mg/24h,判定糖尿病大鼠造模成功。
2.给药:将造模成功后的大鼠随机分为5组,分别为模型对照组、阳性对照组、药物高剂量组、药物中剂量组和药物低剂量组。将实施例1中的苦瓜多肽胶囊内容物加纯净水配制成灌胃药液,当日配制,分别按低剂量组(给药量150mg/kg)、中剂量组(给药量200mg/kg)、高剂量组(给药量400mg/kg)灌胃;给阳性对照组的大鼠灌胃盐酸二甲双胍,给药量200mg/kg;模型对照组和空白组在同等条件下灌胃生理盐水。每组每日灌胃一次,连续给药30天。
3.检测:末次给药2小时后,尾静脉取血,测大鼠血糖含量以及糖化血红蛋白含量,结果如表1所示。
二、实验结果:
表1:实施例1中苦瓜多肽胶囊不同剂量组对大鼠血糖的影响
注:与空白对照组比较,**p<0.01;与模型组比较,#p<0.05,##p<0.01。
由表1可知,相比于空白对照组,模型组的空腹血糖和糖化血红蛋白的含量均大幅升高,说明糖尿病大鼠造模成功。与模型组相比,阳性对照组和给药组(高、中、低剂量组)的空腹血糖和糖化血红蛋白的含量均有所下降,呈现显著性差异,其中,以药物高剂量组下降更为明显,表明该苦瓜多肽复方胶囊对糖尿病有较好的治疗效果,且治疗效果呈剂量依赖性。
另外,将实施例2和实施例3提供的苦瓜多肽复方胶囊用于进行上述实验,结果与实施例1类似,故不逐一列出。
综上所述,本发明提供的苦瓜多肽复方胶囊及其制备方法,基于苦瓜降血糖的现代医学研究及糖尿病的消渴症理论,其包括苦瓜多肽提取物、人参皂苷提取物、葛根黄酮提取物、黄芪多糖提取物以及微量元素铬。首先高效提取、分离、纯化大量具有稳定调控血糖代谢功能的特定分子量和序列的天然活性苦瓜多肽蛋白,含量在20%以上,其胰岛素受体结合能力极强,能激活胰岛受体蛋白信号通路及恢复受损胰岛细胞功能,是有效调控血糖代谢的主要活性成分。另外结合中医药独特配方选用西洋参、葛根、黄芪,以及添加能增强人体胰岛素敏感性的微量元素铬,经复合制成的植物胶囊制剂,质量可控且降血糖效果显著,产品功效稳定,可用于糖尿病的预防或治疗。
尽管已用具体实施例来说明和描述了本发明,然而应意识到,在不背离本发明的精神和范围的情况下可以作出许多其它的更改和修改。因此,这意味着在所附权利要求中包括属于本发明范围内的所有这些变化和修改。
Claims (10)
1.一种降血糖苦瓜多肽复方胶囊,其特征在于,所述苦瓜多肽复方胶囊包括:
3~5重量份的苦瓜多肽提取物,所述苦瓜多肽提取物中苦瓜多肽蛋白的含量在20%以上;
2~4重量份的人参皂苷提取物,所述人参皂苷提取物中人参皂苷的含量在15%以上;
1~3重量份的葛根黄酮提取物,所述葛根提取物中葛根总黄酮的含量在50%以上;
1~3重量份的黄芪多糖提取物,所述黄芪多糖提取物中黄芪多糖的含量在15%以上;以及
微量元素铬0.6~0.8‰。
2.根据权利要求1所述的降血糖苦瓜多肽复方胶囊,其特征在于,所述苦瓜多肽提取物中苦瓜多肽蛋白的含量不低于20%,其中分子量为5.5~7kDa的苦瓜多肽的含量占比例为18~25%。
3.根据权利要求1所述的降血糖苦瓜多肽复方胶囊,其特征在于,所述苦瓜多肽植物复方胶囊还包括药用级或保健食品用辅料,所述辅料包括粘合剂、崩解剂、填充剂或润滑剂中的至少一种或几种,优选为微晶纤维素,抗性糊精,山梨糖醇、预胶化淀粉、交联聚维酮中的一种或几种。
4.根据权利要求1所述的降血糖苦瓜多肽复方胶囊,其特征在于,所述人参皂苷提取物是通过提取人参或西洋参根部制备得到。
5.根据权利要求1所述的降血糖苦瓜多肽复方胶囊,其特征在于,所述微量元素铬选自吡啶甲酸铬或富铬酵母。
6.根据权利要求1所述的降血糖苦瓜多肽复方胶囊,其特征在于,所述葛根总黄酮中葛根素的含量在40%以上。
7.根据权利要求1或2所述的苦瓜多肽复方胶囊,其特征在于,所述苦瓜多肽提取物的制备方法包括:
用净化水浸提苦瓜原料,再离心去渣,得离心液;
将所述离心液经过截留分子量为3μm~0.1μm的微滤膜系统进行过滤,除去大分子杂质,得到微滤膜透过液;
将所述微滤膜透过液经过截留分子量为150kDa的卷式超滤膜纯化系统进行过滤,得超滤膜透过液;将所述超滤膜透过液再经截留分子量为800Da的卷式超滤膜纯化系统进行过滤,得到超滤膜截留液;
将所述截留液经过截留分子量≥100Da的卷式高压反渗透膜系统进行浓缩,除去水分及部分残留无机盐和小分子杂质,得到浓缩液,所述浓缩液的固形物含量≥30%;
将所述浓缩液进行干燥,得到多肽蛋白含量不低于20%的苦瓜多肽提取物粉。
8.根据权利要求7所述的降血糖苦瓜多肽复方胶囊,其特征在于,所述卷式超滤膜纯化系统采用两支膜并联使用,过滤膜为含有聚砜或聚醚砜材料的过滤膜,经过卷式超滤膜系统进行纯化的操作温度为15~35℃,操作压力为0.3~0.8MPa。
9.根据权利要求7所述的降血糖苦瓜多肽复方胶囊,其特征在于,所述卷式高压反渗透膜浓缩系统采用四支膜串联使用,经过卷式高压反渗透膜进行浓缩的操作温度为15~35℃,操作压力为3.5~5.5MPa。
10.一种如权利要求1~9中任一项所述的降血糖苦瓜多肽复方胶囊的制备方法,其特征在于,其包括:
将所述苦瓜多肽提取物、所述人参皂苷提取物、所述葛根黄酮提取物、所述黄芪多糖提取物以及所述微量元素铬与载体辅料混合后干燥过筛、经振动磨式超微粉碎得粒度50μm以下混合粉料;采用湿法制粒法,用羟丙基纤维素HPC的乙醇溶液做粘合剂将所述混合粉料制成湿颗粒后,35~55℃干燥3~5小时并过40目筛网进行整粒,测定含量后依规格填充胶囊。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710833327.0A CN107412721B (zh) | 2017-09-15 | 2017-09-15 | 一种降血糖苦瓜多肽复方胶囊及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710833327.0A CN107412721B (zh) | 2017-09-15 | 2017-09-15 | 一种降血糖苦瓜多肽复方胶囊及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107412721A true CN107412721A (zh) | 2017-12-01 |
CN107412721B CN107412721B (zh) | 2020-11-24 |
Family
ID=60433006
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710833327.0A Active CN107412721B (zh) | 2017-09-15 | 2017-09-15 | 一种降血糖苦瓜多肽复方胶囊及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107412721B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109363186A (zh) * | 2018-10-29 | 2019-02-22 | 电子科技大学中山学院 | 一种植物小分子活性多肽保健胶囊及其制备方法 |
CN110679943A (zh) * | 2019-10-25 | 2020-01-14 | 李玉保 | 具有减肥降脂效果的苦瓜多肽复合营养素及制备方法 |
CN110693025A (zh) * | 2019-11-01 | 2020-01-17 | 东北林业大学 | 一种多功能成分协同降血糖的组合物及其应用 |
CN110801024A (zh) * | 2019-10-25 | 2020-02-18 | 运鸿集团股份有限公司 | 降低血糖血脂及糖化血红蛋白的多糖复合多肽及制备方法 |
CN113812636A (zh) * | 2020-06-18 | 2021-12-21 | 陈信行 | 腐植酸苦瓜胜肽复方及其制程 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1255044A (zh) * | 1997-04-01 | 2000-05-31 | 卡里克斯治疗公司 | 苦瓜中的口服活性成分,其活性肽,及它们治疗糖尿病的用途 |
WO2008000063A1 (en) * | 2006-06-27 | 2008-01-03 | Innovative Life Sciences Corporation | Herbal product comprising cinnamon and bitter melon for treating diabetes |
CN103110697A (zh) * | 2013-02-01 | 2013-05-22 | 北京润康普瑞生物技术有限公司 | 一种具有降血糖作用的药物组合 |
CN103768579A (zh) * | 2012-10-18 | 2014-05-07 | 刘晓峰 | 一种降低血糖的中药及其制备方法 |
CN103989168A (zh) * | 2014-05-23 | 2014-08-20 | 天津大学 | 一种降糖降脂组合物 |
CN104337871A (zh) * | 2014-10-16 | 2015-02-11 | 浙江春宝胶囊有限公司 | 一种降糖胶囊 |
CN106110294A (zh) * | 2016-06-29 | 2016-11-16 | 中科和素(天津)医药科技有限公司 | 一种修复受损胰岛细胞的营养制剂及其制备方法 |
CN106606529A (zh) * | 2016-12-27 | 2017-05-03 | 南京圣诺生物科技实业有限公司 | 一种具有辅助降血糖功效的组合物及其制备方法和应用 |
-
2017
- 2017-09-15 CN CN201710833327.0A patent/CN107412721B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1255044A (zh) * | 1997-04-01 | 2000-05-31 | 卡里克斯治疗公司 | 苦瓜中的口服活性成分,其活性肽,及它们治疗糖尿病的用途 |
WO2008000063A1 (en) * | 2006-06-27 | 2008-01-03 | Innovative Life Sciences Corporation | Herbal product comprising cinnamon and bitter melon for treating diabetes |
CN103768579A (zh) * | 2012-10-18 | 2014-05-07 | 刘晓峰 | 一种降低血糖的中药及其制备方法 |
CN103110697A (zh) * | 2013-02-01 | 2013-05-22 | 北京润康普瑞生物技术有限公司 | 一种具有降血糖作用的药物组合 |
CN103989168A (zh) * | 2014-05-23 | 2014-08-20 | 天津大学 | 一种降糖降脂组合物 |
CN104337871A (zh) * | 2014-10-16 | 2015-02-11 | 浙江春宝胶囊有限公司 | 一种降糖胶囊 |
CN106110294A (zh) * | 2016-06-29 | 2016-11-16 | 中科和素(天津)医药科技有限公司 | 一种修复受损胰岛细胞的营养制剂及其制备方法 |
CN106606529A (zh) * | 2016-12-27 | 2017-05-03 | 南京圣诺生物科技实业有限公司 | 一种具有辅助降血糖功效的组合物及其制备方法和应用 |
Non-Patent Citations (5)
Title |
---|
《中国博士学位论文全文数据库 工程科技I辑》 * |
余元勋等主编: "《中国分子糖尿病学》", 30 April 2016, 安徽科学技术出版社 * |
刘宝山等: "苦瓜及其复方制剂降糖作用的研究进展", 《河北医学》 * |
石永革等主编: "《远离糖尿病有诀窍》", 31 July 2014, 郑州大学出版社 * |
贾利蓉等主编: "《保健食品营养》", 30 June 2006, 四川大学出版社 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109363186A (zh) * | 2018-10-29 | 2019-02-22 | 电子科技大学中山学院 | 一种植物小分子活性多肽保健胶囊及其制备方法 |
CN110679943A (zh) * | 2019-10-25 | 2020-01-14 | 李玉保 | 具有减肥降脂效果的苦瓜多肽复合营养素及制备方法 |
CN110801024A (zh) * | 2019-10-25 | 2020-02-18 | 运鸿集团股份有限公司 | 降低血糖血脂及糖化血红蛋白的多糖复合多肽及制备方法 |
GB2608697B (en) * | 2019-10-25 | 2023-11-15 | China Yunhong Holdings Co Ltd | Polysaccharide-peptide complex for lowering blood sugar, blood lipid and glycosylated hemoglobin levels, and preparation method |
CN110693025A (zh) * | 2019-11-01 | 2020-01-17 | 东北林业大学 | 一种多功能成分协同降血糖的组合物及其应用 |
CN113812636A (zh) * | 2020-06-18 | 2021-12-21 | 陈信行 | 腐植酸苦瓜胜肽复方及其制程 |
Also Published As
Publication number | Publication date |
---|---|
CN107412721B (zh) | 2020-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107412721A (zh) | 一种降血糖苦瓜多肽复方胶囊及其制备方法 | |
CN107412720A (zh) | 一种治疗糖尿病的苦瓜多肽复方植物药及其制备方法 | |
CN105063139B (zh) | 一种用于醒酒的沙棘籽多肽的制备方法 | |
CN110051726A (zh) | 一种青钱柳叶中总黄酮和总多糖的制备方法及应用 | |
CN107581620A (zh) | 一种降血糖苦瓜多肽复合含片及其制备方法 | |
CN104621296A (zh) | 一种具有调节血脂、血糖、血压功能的中药组合茶饮料 | |
CN109601795A (zh) | 以赶黄草为主要原料的组合物解酒饮料及其制备方法 | |
CN101401829A (zh) | 一种野金柴活性提取物及其制备方法和应用 | |
CN109692194B (zh) | 一种治疗糖尿病肾病的复方中药组合物及其制备方法和应用 | |
CN107455663A (zh) | 糖尿病患者的多肽食疗面条及其制备方法 | |
CN102784182A (zh) | 红参多糖提取物的制备方法 | |
CN110075266A (zh) | 一种养肾固肾补气血的配方及制备方法 | |
CN107468744A (zh) | 一种全程低温生产苦瓜多肽蛋白提取物的新方法、苦瓜多肽蛋白提取物及其应用 | |
CN105943569A (zh) | 一种青梅有效成分的提取方法 | |
WO2021078288A1 (zh) | 活化胰岛素及治疗糖尿病的复合苦瓜肽口服药及制备方法 | |
CN107495020A (zh) | 一种糖尿病人群适宜的多肽饮料水及其制备工艺 | |
CN107594541A (zh) | 一种制备苦瓜多肽蛋白的膜分离纯化技术工艺、苦瓜多肽蛋白提取物及其应用 | |
CN107041924A (zh) | 一种防治糖尿病肾病的朝药复方提取物及其制备方法 | |
CN104910291B (zh) | 一种木菠萝叶多糖及其制备方法和应用 | |
CN108077512B (zh) | 辣木叶降糖茶及其制备方法 | |
CN110101729A (zh) | 人参茎叶有效部位及其提取方法和降血糖应用 | |
CN105902857A (zh) | 一种黄芪玉米须枸杞子降血糖口服液及其制备方法 | |
CN108143787A (zh) | 一种葛根、枳椇子复合黄酮的制备方法 | |
CN108041558A (zh) | 一种养生酱油及其制备方法 | |
CN103479875A (zh) | 一种高活性玉竹浓缩液的制备方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 435400 Hubei province Huanggang city Wuxue city Wuxue Street Xing Village 170 Applicant after: Li Yubao Applicant after: He Jingren Applicant after: Yunhong Group Co.,Ltd. Address before: No. 170, Xingjia village, Wuxue street, Huanggang, Hubei Province Applicant before: Li Yubao Applicant before: He Jingren Applicant before: HUBEI YUNHONG ENERGY GROUP Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |